Skip to content
Business Company News, Medical Health Aged Care

Diag-Nose.io Closes Oversubscribed $3.15M Seed Round to Revolutionise Respiratory Care with AI-Driven Precision

Diag-Nose.io 2 mins read

Melbourne, Australia, 30th January 2025 – A groundbreaking precision medicine system developed by Australian biotech trailblazer Diag-Nose.io is set to transform the management of chronic respiratory diseases worldwide after closing its seed round this week. Originally established at the Stanford ENT Innovation Program and now based in Melbourne, Diag-Nose.io is pioneering advancements in respiratory healthcare by focusing on the “unified airway”; the biological relationship between the lungs and nasal passages.

Traditional diagnostic methods for chronic respiratory conditions - such as asthma and chronic obstructive pulmonary disorder (COPD) - rely on outdated measurement tools and subjective assessments. These flawed processes currently result in treatment failure for more than 30% of patients, costing hundreds of millions of dollars per year.

Using artificial intelligence and protein signatures, Diag-Nose.io’s RhinoMAP removes the guesswork, enabling clinicians to match treatments to a patient’s unique biological profile, or “endotype.”

A nasal sample is collected using Diag-Nose.io’s patented nasal liquid biopsy device and analysed. The data is then uploaded into RhinoMAP, an AI-powered biomarker analytics platform to determine disease progression and therapeutic responsiveness and in the long-term differential diagnostic recommendation.

“Over a third of Australians suffer from chronic respiratory conditions, and globally, these diseases impact more than 450 million people, resulting in approximately four million deaths in 2019,” said Eldin Rostom, CEO and Co-Founder of Diag-Nose.io. “Together with the new biologics medicines, our RhinoMAP system will bring us one step closer towards the holy grail of respiratory medicine; helping patients become completely free of symptoms. This progress is only made possible thanks to the dedicated support and investment from visionary partners who share our mission.

The oversubscribed $3.15M raise was led by Breakthrough Victoria. Additional funding comes from Radar Ventures, Specialty Physician Associates, biotech executives Carl Stubbings - who will also be appointed to the Board, Stephen Ho and Richard Lipscombe alongside an international syndicate of physicians from leading hospitals including Houston Methodist and Mount Sinai.

-ENDS-

 


Key Facts:

- Diag-Nose.io Closes Oversubscribed $3.15M Seed Round

- Brings new hope for Aussie asthma sufferers with "AI enabled unified airway"

Asthma deaths have returned to pre-pandemic levels.

- One third of Australian's suffer from chronic respiratory conditions, and globally, these diseases impact more than 450 million people, resulting in approximately four million deaths.

- Outdated measurement tools mean diagnosis and treatment fails in more than 30% of patients.


About us:

ABOUT DIAG-NOSE.IO

Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.

Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.

The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

 


Contact details:

For any questions in relation to this release or to discuss interviews, please contact:

 

Nicole Papoutsis

media@diag-nose.io

0422 418 099

 

Media

More from this category

  • Medical Health Aged Care, Sport Recreation
  • 09/02/2025
  • 11:45
Sports Medicine Australia

Media Call: Concussion campaign aims to to keep kids safe

Sports Medicine Australia is launching a nationwide campaign to help coaches, teachers and sport medicine professionals safely manage the 100,000 sport-related concussions in Australia…

  • Contains:
  • Medical Health Aged Care
  • 09/02/2025
  • 08:41
Royal Australian College of GPs

RACGP applauds Albanese Government’s $573m women’s health package

The Royal Australian College of GPs has applauded the Federal Government’s $573.3 million package for women’s health which includes new funding for menopause health assessments and increased funding for long-acting reversible contraception (LARCs). The Albanese Government package announced today includes more funding for LARC insertion and removal, and to establish LARC training centres. It also includes new funding for menopause health assessments, the development of national guidelines for menopause and perimenopause, and for new generation contraceptive pills to be listed on the Pharmaceutical Benefits Scheme (PBS). RACGP President Dr Michael Wright said: “The RACGP has been calling for more funding…

  • Medical Health Aged Care, Political
  • 09/02/2025
  • 07:34
Monash University

Postcode and income no longer a barrier: improved access to long-acting reversible contraception is a game changer

Today’s federal government announcement of over $570 million to improve women’s health has been welcomed by one of Australia’s foremost experts on women’s reproductive…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.